Stocks to watch: Nazara Technologies, HDFC, HCL Technologies, Indiabulls Real Estate, Wipro

• Follow

Here is the list of top stocks that could be in focus on April 23.

Nazara Technologies: The company has entered into a Share Purchase Agreement (SPA) on April 22, 2021 with Sankalp Sharma and Absolute Sports (ASPL) for acquisition of further stake of 1.40% equity stake (on fully diluted basis) for a consideration of Rs 96.16 lakh in ASPL, a subsidiary of the Company. Post completion of the said transaction, the stake of the Company in ASPL shall increase from 63.90% to 65.30%.

Earnings today: HCL Technologies, Indiabulls Real Estate and Mahindra & Mahindra Financial are slated to announce their financial results for the March quarter on Friday.

Hazoor Multi Projects: The company has received work order of Rs 6,84,00,000 for completion of Balance work of ‘National Highway No 548-A from Section Waken Pali to 2 lane with paved shoulder’ from Varaha Infra.

Housing Development Finance Corporation (HDFC): The company has concluded the sale of 47,75,241 equity shares of Re 1 each, representing 24.48% of the equity capital of Good Host Spaces (Good Host) to Baskin Lake Investments, at a price of Rs 452.71 per equity share, aggregating to a consideration of Rs 216.18 crore. Post sale, Good Host has ceased to be an associate of the Corporation.

TCPL Packaging: The company has subscribed additional 10,00,000 fully paid up equity shares of face value of Rs 10 each of TCPL Innofilms, the wholly-owned subsidiary of the Company.

Wipro: The IT firm is going to achieving Net-Zero Greenhouse Gas (GHG) emissions by 2040 in line with the objective of the Paris Agreement to cap temperature rise to 1.5 degree Celsius. The company also set an intermediate target of a 55 per cent reduction in GHG emissions by 2030 in absolute emission levels compared to its base year of 2016-17 (April-March).

Gland Pharma: The company has received approval from the United States Food and Drug Administration (US FDA) for generic Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) Single-Dose Bag for Infusion. Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir Injection, 24 mg/mL, of Clinigen Healthcare. With this approval, Gland Pharma secured the first generic offering status in Single-Dose Bag for Infusion.

Cyient: Cyient has reported results for fourth quarter and year ended March 31, 2021. The company has reported net profit of Rs 46.10 crore for the quarter under review against net loss of Rs 1 crore for the same quarter in the previous year. However, total income of the company decreased by 7.14% at Rs 347 crore for Q4FY21 as compared Rs 373.70 crore for the corresponding quarter previous year. On the consolidated basis, the company has reported over 2-fold jump in its net profit at Rs 103.10 crore for the quarter under review as compared to Rs 45.20 crore for the same quarter in the previous year. Total income of the company marginally increased by 0.52% at Rs 1,133.40 crore for Q4FY21 as compared Rs 1,127.50 crore for the corresponding quarter previous year.